Transplant Pathology

  • Desley A. H. NeilEmail author


This chapter provides a general overview of the diagnosis of acute cellular rejection, antibody mediated rejection and chronic vascular rejection (graft vasculopathy). It describes how to differentiate these from the mimics of rejection. Also described are other entities encountered in cardiac transplant recipients, including peritransplant injury both in endomyocardial biopsies and failed allografts, infections and post transplant lymphoproliferative disorders. The examination of a failed allograft is discussed.


Heart transplant Rejection Quilty Antibody mediated rejection Allograft vasculopathy Chronic vascular rejection Post-transplant lymphoproliferative disorder Infection Allograft Previous biopsy site 


  1. 1.
    Capoccia M. Mechanical circulatory support for advanced heart failure: are we about to witness a new “gold standard”? J Cardiovasc Dev Dis. 2016;3:35.PubMedCentralCrossRefGoogle Scholar
  2. 2.
    Phan K, Huo YR, Zhao DF, Yan TD, Tchantchaleishvili V. Ventricular recovery and pump explantation in patients supported by left ventricular assist devices: a systematic review. ASAIO J. 2016;62:219–31.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Khush K, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult heart transplantation report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37:1155–68.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Hogg R, Rushton S, Cardiothoracic Advisory Group Clinical Audit Group. Annual report on cardiothoracic organ transplantation 2017-18. NHSBT and NHSE [2017-18]. Watford: NHSBT; 2018. p. 1–150.Google Scholar
  5. 5.
    Hamour IM, Khaghani A, Kanagala PK, Mitchell AG, Banner NR. Current outcome of heart transplantation: a 10-year single centre perspective and review. QJM. 2010;104:335–43.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Crespo-Leiro MG, Barge-Caballero E, Marzoa-Rivas R, Paniagua-Martin MJ. Heart transplantation. Curr Opin Organ Transplant. 2010;15:633–8.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Tan CD, Baldwin WM III, Rodriguez ER. Update on cardiac transplantation pathology. Arch Pathol Lab Med. 2007;131:1169–91.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Billingham ME. Some recent advances in cardiac pathology. Hum Pathol. 1979;10:367–86.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. The International Society for Heart Transplantation. J Heart Transplant. 1990;9:587–93.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710–20.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Spiegelhalter DJ, Stovin PG. An analysis of repeated biopsies following cardiac transplantation. Stat Med. 1983;2:33–40.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Sharples LD, Cary NR, Large SR, Wallwork J. Error rates with which endomyocardial biopsy specimens are graded for rejection after cardiac transplantation. Am J Cardiol. 1992;70:527–30.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30:252–69.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Berry G, Angelini A, Burke M, et al. The ISHLT Working formulation for pathological diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant. 2011;30:601.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Behr TM, Feucht HE, Richter K, et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant. 1999;18:904–12.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 1993;43:1333–8.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant. 2005;5:2778–85.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25:153–9.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Stewart S, Cary NRB. The pathology of heart and lung transplantation. Curr Diagn Pathol. 1996;3:69–79.CrossRefGoogle Scholar
  20. 20.
    Suvarna SK, Kennedy A, Ciulli F, Locke TJ. Revision of the 1990 working formulation for cardiac allograft rejection: the Sheffield experience. Heart. 1998;79:432–6.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Maleszewski JJ, Kucirka LM, Segev DL, Halushka MK. Survey of current practice related to grading of rejection in cardiac transplant recipients in North America. Cardiovasc Pathol. 2011;20:261.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Hook S, Caple JF, McMahon JT, Myles JL, Ratliff NB. Comparison of myocardial cell injury in acute cellular rejection versus acute vascular rejection in cyclosporine-treated heart transplants. J Heart Lung Transplant. 1995;14:351–8.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Howie AJ. C9 immunohistology in detection of myocardial infarction. J Pathol. 2001;193:421.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Robert-Offerman SR, Leers MP, van Suylen RJ, Nap M, Daemen MJ, Theunissen PH. Evaluation of the membrane attack complex of complement for the detection of a recent myocardial infarction in man. J Pathol. 2000;191:48–53.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Yasojima K, Schwab C, McGeer EG, McGeer PL. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res. 1998;83:860–9.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol. 2004;19:166–9.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Hammond EH, Hansen JK, Spencer LS, Jensen A, Yowell RL. Immunofluorescence of endomyocardial biopsy specimens: methods and interpretation. J Heart Lung Transplant. 1993;12:S113–24.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant. 1989;8:430–43.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Olsen SL, Wagoner LE, Hammond EH, et al. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J Heart Lung Transplant. 1993;12:S135–42.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Bonnaud EN, Lewis NP, Masek MA, Billingham ME. Reliability and usefulness of immunofluorescence in heart transplantation. J Heart Lung Transplant. 1995;14:163–71.PubMedGoogle Scholar
  31. 31.
    Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation. 2001;71:652–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Chantranuwat C, Qiao JH, Kobashigawa J, Hong L, Shintaku P, Fishbein MC. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence. Appl Immunohistochem Mol Morphol. 2004;12:166–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Miller DV, Roden AC, Gamez JD, Tazelaar HD. Detection of C4d deposition in cardiac allografts: a comparative study of immunofluorescence and immunoperoxidase methods. Arch Pathol Lab Med. 2010;134:1679–84.PubMedGoogle Scholar
  34. 34.
    Lones MA, Czer LS, Trento A, Harasty D, Miller JM, Fishbein MC. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant. 1995;14:151–62.PubMedGoogle Scholar
  35. 35.
    Ratliff NB, McMahon JT. Activation of intravascular macrophages within myocardial small vessels is a feature of acute vascular rejection in human heart transplants. J Heart Lung Transplant. 1995;14:338–45.PubMedGoogle Scholar
  36. 36.
    Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4:1033–41.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28:417–22.PubMedCrossRefGoogle Scholar
  38. 38.
    Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant. 2009;9:2075–84.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant. 2009;28:781–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32:1147–62.PubMedCrossRefGoogle Scholar
  41. 41.
    Forbes RD, Rowan RA, Billingham ME. Endocardial infiltrates in human heart transplants: a serial biopsy analysis comparing four immunosuppression protocols. Hum Pathol. 1990;21:850–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Gajjar NA, Kobashigawa JA, Laks H, Espejo-Vassilakis M, Fishbein MC. FK506 vs. cyclosporin. Pathologic findings in 1067 endomyocardial biopsies. Cardiovasc Pathol. 2003;12:73–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Barone JH, Fishbein MC, Czer LS, Blanche C, Trento A, Luthringer DJ. Absence of endocardial lymphoid infiltrates (Quilty lesions) in nonheart transplant recipients treated with cyclosporine. J Heart Lung Transplant. 1997;16:600–3.PubMedGoogle Scholar
  44. 44.
    Sattar HA, Husain AN, Kim AY, Krausz T. The presence of a CD21+ follicular dendritic cell network distinguishes invasive Quilty lesions from cardiac acute cellular rejection. Am J Surg Pathol. 2006;30:1008–13.PubMedCrossRefGoogle Scholar
  45. 45.
    Di Carlo E, D’Antuono T, Contento S, Di NM, Ballone E, Sorrentino C. Quilty effect has the features of lymphoid neogenesis and shares CXCL13-CXCR5 pathway with recurrent acute cardiac rejections. Am J Transplant. 2007;7:201–10.PubMedCrossRefGoogle Scholar
  46. 46.
    Marboe CC, Billingham M, Eisen H, et al. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant. 2005;24:S219–26.PubMedCrossRefGoogle Scholar
  47. 47.
    Hiemann NE, Knosalla C, Wellnhofer E, Lehmkuhl HB, Hetzer R, Meyer R. Quilty in biopsy is associated with poor prognosis after heart transplantation. Transpl Immunol. 2008;19:209–14.PubMedCrossRefGoogle Scholar
  48. 48.
    Hiemann NE, Knosalla C, Wellnhofer E, Lehmkuhl HB, Hetzer R, Meyer R. Quilty indicates increased risk for microvasculopathy and poor survival after heart transplantation. J Heart Lung Transplant. 2008;27:289–96.PubMedCrossRefGoogle Scholar
  49. 49.
    Chantranuwat C, Blakey JD, Kobashigawa JA, et al. Sudden, unexpected death in cardiac transplant recipients: an autopsy study. J Heart Lung Transplant. 2004;23:683–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Yamani MH, Ratliff NB, Starling RC, et al. Quilty lesions are associated with increased expression of vitronectin receptor (alphavbeta3) and subsequent development of coronary vasculopathy. J Heart Lung Transplant. 2003;22:687–90.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Zakliczynski M, Nozynski J, Konecka-Mrowka D, et al. Quilty effect correlates with biopsy-proven acute cellular rejection but does not predict transplanted heart coronary artery vasculopathy. J Heart Lung Transplant. 2009;28:255–9.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Sibley RK, Olivari MT, Ring WS, Bolman RM. Endomyocardial biopsy in the cardiac allograft recipient. A review of 570 biopsies. Ann Surg. 1986;203:177–87.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Connor RC. Heart damage associated with intracranial lesions. Br Med J. 1968;3:29–31.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Connor RC. Focal myocytolysis and fuchsinophilic degeneration of the myocardium of patients dying with various brain lesions. Ann N Y Acad Sci. 1969;156:261–70.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Connor RC. Myocardial damage secondary to brain lesions. Am Heart J. 1969;78:145–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Connor RC. Fuchsinophilic degeneration of myocardium in patients with intracranial lesions. Br Heart J. 1970;32:81–4.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Haddad F, Deuse T, Pham M, et al. Changing trends in infectious disease in heart transplantation. J Heart Lung Transplant. 2010;29:306–15.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Breinholt JP, Moulik M, Dreyer WJ, et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J Heart Lung Transplant. 2010;29:739–46.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Moulik M, Breinholt JP, Dreyer WJ, et al. Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients. J Am Coll Cardiol. 2010;56:582–92.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Kotton CN. Update on infectious diseases in pediatric solid organ transplantation. Curr Opin Organ Transplant. 2008;13:500–5.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Casadei D. Chagas’ disease and solid organ transplantation. Transplant Proc. 2010;42:3354–9.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Kotton CN, Lattes R. Parasitic infections in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S234–51.PubMedCrossRefGoogle Scholar
  63. 63.
    Derouin F, Pelloux H. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect. 2008;14:1089–101.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Sanchez MA, Debrunner M, Cox E, Caldwell R. Acquired toxoplasmosis after orthotopic heart transplantation in a sulfonamide-allergic patient. Pediatr Cardiol. 2011;32:91–3.CrossRefGoogle Scholar
  65. 65.
    Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol. 2010;149:675–92.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med. 2007;131:1209–18.PubMedGoogle Scholar
  67. 67.
    Grivas PD. Post-transplantation lymphoproliferative disorder (PTLD) twenty years after heart transplantation: a case report and review of the literature. Med Oncol. 2011;28:829.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Manlhiot C, Pollock-Barziv SM, Holmes C, et al. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant. 2010;29:648–57.PubMedCrossRefGoogle Scholar
  69. 69.
    Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, Krawczyk M, Lerut J, Paczek L. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant. 2010;25:2089–98.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva: World Health Organisation; 2008.Google Scholar
  71. 71.
    Turillazzi E, Pennella A, Di GG, Neri M, Fineschi V. Post-transplant lymphoproliferative disorder in the heart late after heterotopic transplantation: autopsy findings. J Heart Lung Transplant. 2010;29:904–6.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Luk A, Metawee M, Ahn E, Gustafsson F, Ross H, Butany J. Do clinical diagnoses correlate with pathological diagnoses in cardiac transplant patients? The importance of endomyocardial biopsy. Can J Cardiol. 2009;25:e48–54.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Neil D. Recurrent and de novo disease in kidney, heart, lung, pancreas and intestinal transplants. Curr Opin Organ Transplant. 2006;11:289–95.CrossRefGoogle Scholar
  74. 74.
    Alloni A, Pellegrini C, Ragni T, et al. Heart transplantation in patients with amyloidosis: single-center experience. Transplant Proc. 2004;36:643–4.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23:1142–53.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Kristen AV, Meyer FJ, Perz JB, et al. Risk stratification in cardiac amyloidosis: novel approaches. Transplantation. 2005;80:S151–5.PubMedCrossRefGoogle Scholar
  77. 77.
    Kristen AV, Sack FU, Schonland SO, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail. 2009;11:1014–20.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Mignot A, Varnous S, Redonnet M, et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis. 2008;101:523–32.PubMedCrossRefGoogle Scholar
  79. 79.
    Sattianayagam PT, Gibbs SD, Pinney JH, et al. Solid organ transplantation in AL amyloidosis. Am J Transplant. 2010;10:2124–31.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Moloney ED, Egan JJ, Kelly P, Wood AE, Cooper LT Jr. Transplantation for myocarditis: a controversy revisited. J Heart Lung Transplant. 2005;24:1103–10.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Luk A, Lee A, Ahn E, Soor GS, Ross HJ, Butany J. Cardiac sarcoidosis: recurrent disease in a heart transplant patient following pulmonary tuberculosis infection. Can J Cardiol. 2010;26:e273–5.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Oni AA, Hershberger RE, Norman DJ, et al. Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant. 1992;11:367–9.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Strecker T, Zimmermann I, Wiest GH. Pulmonary and cardiac recurrence of sarcoidosis in a heart transplant recipient. Dtsch Med Wochenschr. 2007;132:1159–62.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Yager JE, Hernandez AF, Steenbergen C, et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant. 2005;24:1988–90.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Adam B, Mengel M. Transplant biopsy beyond light microscopy. BMC Nephrol. 2015;16:132.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Halloran PF, Potena L, Van Huyen JD, et al. Building a tissue-based molecular diagnostic system in heart transplant rejection: the heart molecular microscope diagnostic (MMDx) System. J Heart Lung Transplant. 2017;36:1192–200.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Loupy A, Duong Van Huyen JP, Hidalgo L, et al. Gene expression profiling for the identification and classification of antibody-mediated heart rejection. Circulation. 2017;135:917–35.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Halloran PF, Reeve J, Aliabadi AZ, et al. Exploring the cardiac response to injury in heart transplant biopsies. JCI Insight. 2018;3:123674.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Afzali B, Chapman E, Racape M, et al. Molecular assessment of microcirculation injury in formalin-fixed human cardiac allograft biopsies with antibody-mediated rejection. Am J Transplant. 2017;17:496–505.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Halloran PF, Venner JM, Madill-Thomsen KS, et al. Review: the transcripts associated with organ allograft rejection. Am J Transplant. 2018;18:785–95.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Vassalli G, Gallino A, Weis M, et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J. 2003;24:1180–8.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Demetris AJ, Zerbe T, Banner B. Morphology of solid organ allograft arteriopathy: identification of proliferating intimal cell populations. Transplant Proc. 1989;21:3667–9.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc. 1987;19:19–25.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Billingham ME. Graft coronary disease: the lesions and the patients. Transplant Proc. 1989;21:3665–6.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Eisen HJ. Pathogenesis and management of cardiac allograft vasculopathy. Curr Opin Organ Transplant. 2004;9:448–52.CrossRefGoogle Scholar
  96. 96.
    Pratschke J, Volk HD. Brain death-associated ischemia and reperfusion injury. Curr Opin Organ Transplant. 2004;9:153–8.CrossRefGoogle Scholar
  97. 97.
    Mehra MR, Uber PA, Ventura HO, Scott RL, Park MH. The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol. 2004;43:806–10.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Cohen O, De La Zerda DJ, Beygui R, Hekmat D, Laks H. Donor brain death mechanisms and outcomes after heart transplantation. Transplant Proc. 2007;39:2964–9.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Neil DA, Lynch SV, Hardie IR, Effeney DJ. Cold storage preservation and warm ischaemic injury to isolated arterial segments: endothelial cell injury. Am J Transplant. 2002;2:400–9.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Neil DA, Maguire SH, Walsh M, Lynch SV, Hardie IR, Effeney DJ. Progression of changes in arteries following cold storage preservation in UW and Collins solution in a syngeneic aortic transplant model. Transplant Proc. 1997;29:2561–2.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Hiemann NE, Musci M, Wellnhofer E, Meyer R, Hetzer R. Light microscopic biopsy findings after heart transplantation and possible links to development of graft vessel disease. Transplant Proc. 1999;31:149–51.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Koch A, Bingold TM, Oberlander J, et al. Capillary endothelia and cardiomyocytes differ in vulnerability to ischemia/reperfusion during clinical heart transplantation. Eur J Cardiothorac Surg. 2001;20:996–1001.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Kupiec-Weglinski JW. Ischemia and reperfusion injury. Curr Opin Organ Transplant. 2004;9:130–1.CrossRefGoogle Scholar
  104. 104.
    Logani S, Saltzman HE, Kurnik P, Eisen HJ, Ledley GS. Clinical utility of intravascular ultrasound in the assessment of coronary allograft vasculopathy: a review. J Interv Cardiol. 2011;24:9–14.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Stary HC, Blankenhorn DH, Chandler AB, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1992;85:391–405.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Gao SZ, Schroeder JS, Alderman EL, et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation. 1987;76:V56–61.PubMedPubMedCentralGoogle Scholar
  107. 107.
    Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res. 2004;61:461–70.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol. 2010;106:360–8.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Nijboer WN, Schuurs TA, Van der Hoeven JAB, Ploeg RJ. Effect of brain death and donor treatment on organ inflammatory response and donor organ viability. Curr Opin Organ Transplant. 2004;9:110–5.CrossRefGoogle Scholar
  110. 110.
    Van der Hoeven JAB, Ploeg RJ. Effects of brain death on donor organ viability. Curr Opin Organ Transplant. 2001;6:75–82.CrossRefGoogle Scholar
  111. 111.
    Rodriguez-Sinovas A, Abdallah Y, Piper HM, Garcia-Dorado D. Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction. Heart Fail Rev. 2007;12:207–16.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Inserte J, Garcia-Dorado D, Ruiz-Meana M, et al. Effect of inhibition of Na(+)/Ca(2+) exchanger at the time of myocardial reperfusion on hypercontracture and cell death. Cardiovasc Res. 2002;55:739–48.PubMedCrossRefGoogle Scholar
  113. 113.
    Miller DL, Li P, Dou C, Armstrong WF, Gordon D. Evans blue staining of cardiomyocytes induced by myocardial contrast echocardiography in rats: evidence for necrosis instead of apoptosis. Ultrasound Med Biol. 2007;33:1988–96.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Boyle JJ, Rassl DM, Neil D, Suvarna K, Doran H. Heart dissection - explants post cardiac transplantation. In: Boyle JJ, editor. Tissue Pathways for cardiovascular pathology. London: Royal College of Pathologists; 2008. p. 20–1.Google Scholar
  115. 115.
    Boyle JJ, Rassl DM, Neil D, Suvarna K, Doran H. Autopsy cardiac dissection. In: Boyle JJ, editor. Tissue pathways for cardiovascular pathology. London: Royal College of Pathologists; 2008. p. 22–7.Google Scholar
  116. 116.
    Basso C, Burke M, Fornes P, et al. Guidelines for autopsy investigation of sudden cardiac death. Virchows Arch. 2008;452:11–8.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Suvarna SK. National guidelines for adult autopsy cardiac dissection and diagnosis--are they achievable? A personal view. Histopathology. 2008;53:97–112.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Cellular Pathology, Level-1Queen Elizabeth Hospital BirminghamEdgbastonUK

Personalised recommendations